8-K: Cadrenal Acquires Phase 2 HIT Drug VLX-1005, Bolstering Pipeline

Cadrenal Therapeutics has acquired VLX-1005, a first-in-class Phase 2 12-LOX inhibitor for Heparin-Induced Thrombocytopenia (HIT), significantly strengthening its anticoagulation pipeline.

Summary

• Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) acquired VLX-1005 and related 12-lipoxygenase (12-LOX) assets from Veralox Therapeutics Inc. on December 10, 2025.
• The acquisition price includes a $200,000 cash payment, assumption of certain liabilities, contingent milestone payments up to $15 million, and royalties on future global sales.
• Milestone payments are tied to clinical and regulatory achievements: $2 million for first patient dosing in a post-closing clinical trial for VLX-1005, $8 million for first US regulatory approval, $2 million for first ex-US regulatory approval, $2 million for US approval of a subsequent indication, and $1 million for ex-US approval of a subsequent indication.
• Royalty payments to Veralox will be 5% on Annual Net Sales of each Product covered by a Valid Patent Claim, with potential reductions for generic competition or third-party licensing costs.
• Cadrenal also assumed certain obligations under an Amended and Restated Exclusive License Agreement with Old Dominion University (successor to Eastern Virginia Medical School), including aggregate milestone payments of $300,000 due in 2031 (Japan/EU approval) and 2032 (US approval).
• Assumed royalties to Old Dominion University are 2% on worldwide net sales up to $200 million and 3% on sales exceeding $200 million, with minimum annual royalties waived until May 1, 2029.
• Cadrenal will pay $98,169.74 in Past Patent Costs to Old Dominion University at $10,000 per calendar quarter starting March 31, 2026.
• VLX-1005 is a novel, potent, selective small-molecule inhibitor of 12-LOX, targeting the immune-driven biology of HIT, a condition affecting an estimated 56,000 confirmed diagnoses annually in the US.
• The drug has received Orphan Drug Designation and Fast Track designation from the U.S. FDA, and orphan drug status from the European Medicines Agency.
• Interim results from a Phase 2 study (VLX-1005-003) in suspected HIT patients showed encouraging reductions in thromboembolic events.
• Cadrenal's pipeline now includes VLX-1005, tecarfarin (oral VKA for ESKD/AFib and LVAD patients), and frunexian (parenteral Factor XIa antagonist for acute hospital settings).

Sentiment

Score: 8

Explanation: The acquisition of a first-in-class, late-stage asset with Orphan Drug and Fast Track designations for a high-unmet-need indication is a strong positive. The strategic fit and potential market size are significant. While there are future payment obligations, they are contingent on success, aligning incentives. The company's existing cash position will require careful management for ongoing development.

Positives

• The acquisition immediately strengthens Cadrenal's pipeline with a late-stage, first-in-class drug candidate, VLX-1005, targeting a critical immune signaling pathway.
• VLX-1005 addresses an underserved therapeutic opportunity in the $40 billion global anticoagulation market, with the HIT market alone estimated at $1 billion in the US and EU.
• VLX-1005 has a unique mechanism of action (MoA) that directly addresses the pathogenesis of HIT, unlike current standard-of-care anticoagulants which only attenuate thrombus formation.
• The drug has demonstrated a favorable safety profile in Phase 1 studies, being well-tolerated with no serious adverse events.
• Interim Phase 2 results showed encouraging reductions in thromboembolic events, a clinically meaningful endpoint for regulators, clinicians, and payers.
• VLX-1005 has received Orphan Drug Designation and Fast Track designation from the U.S. FDA, and orphan drug status from the European Medicines Agency, potentially accelerating its development and review.
• The acquisition structure, with contingent milestone and royalty payments, allows Cadrenal to allocate capital efficiently to advance clinical development.
• The company now possesses a diversified pipeline of three clinical-stage assets, targeting rare and high-risk patient populations in anticoagulation management.

Negatives

• The acquisition involves significant contingent milestone payments up to $15 million and ongoing royalty obligations, which could become substantial liabilities if VLX-1005 is successful.
• Cadrenal also assumed additional milestone and royalty payment obligations to Old Dominion University, adding to future financial commitments.
• The company's cash position was $3.9 million as of September 30, 2025, while operating expenses for the nine months ended September 30, 2025, were $8.8 million, indicating a need for careful capital management for ongoing development.

Risks

• Forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from expectations.
• The ability to successfully complete clinical trials on time and achieve desired results and benefits as expected is not guaranteed.
• There is a risk in obtaining regulatory approvals for commercialization of product candidates or complying with ongoing regulatory requirements.
• The company's ability to raise capital when needed is a factor that could impact future performance.
• The competitive environment of the business poses a risk to market penetration and success.

Future Outlook

Cadrenal Therapeutics anticipates advancing VLX-1005 for the treatment of HIT, continuing to develop novel therapeutics for high-risk patients, and believes the emerging data from VLX-1005 suggests meaningful potential to improve patient outcomes while maintaining a favorable safety profile. The company views VLX-1005 as a compelling strategic addition to its pipeline, with the agreement's structure enabling capital allocation to its clinical development.

Management Comments

• Matthew Boxer, Co-Founder of Veralox Therapeutics, expressed pleasure that VLX-1005's advancement for HIT treatment will continue under Cadrenal's leadership, noting its alignment with a shared vision and excitement for 12-LOX technology's promise for patients.
• Quang X. Pham, Chairman and CEO of Cadrenal Therapeutics, stated that the company continues to advance novel therapeutics to treat or prevent thrombosis in high-risk patients, emphasizing that HIT remains a dangerous condition without a therapy addressing its immune-driven biology. He believes VLX-1005's emerging data suggests meaningful potential for improved patient outcomes with favorable tolerability, making it a compelling strategic addition to the pipeline given the $1 billion US and EU market size for HIT.

Industry Context

The acquisition of VLX-1005 positions Cadrenal Therapeutics to address a significant unmet need within the broader $40 billion global anticoagulation market. HIT, a life-threatening complication of heparin use, currently lacks therapies that target its immune-driven biology, with existing treatments primarily managing thrombotic complications and carrying bleeding risks. VLX-1005's first-in-class 12-LOX inhibition offers a novel approach, potentially differentiating Cadrenal in a market segment ripe for innovation, especially given the rising rates of thromboembolic events in current HIT populations.

Comparison to Industry Standards

• VLX-1005 is highlighted as the first and only potent, highly selective inhibitor of human 12-LOX in clinical testing, distinguishing it from related compounds and conventional anticoagulants.
• Current standard of care (SoC) for HIT, such as argatroban, primarily attenuates thrombus formation but does not address the underlying immune-driven cause of HIT, and can cause severe bleeding. VLX-1005's unique MoA targets both platelet activation and thrombus formation.
• Preclinical data for VLX-1005 demonstrated inhibition of thrombus formation without increasing bleeding times, in contrast to conventional anticoagulants like argatroban.
• VLX-1005 showed significant inhibition of pulmonary embolism in an animal model of HIT, an area where standard of care (argatroban) had no impact.
• The drug's Orphan Drug and Fast Track designations from the FDA, along with orphan drug status from the EMA, indicate recognition of its potential to address a serious condition with unmet medical needs, potentially offering a faster path to market compared to typical drug development timelines.

Stakeholder Impact

• Shareholders: Potential for significant value creation if VLX-1005 successfully progresses through clinical development and commercialization, given its first-in-class status and large target market. However, future contingent payments and ongoing development costs will impact financial performance.
• Patients with HIT: Direct positive impact through the potential availability of a novel therapeutic that addresses the underlying cause of HIT, offering improved outcomes and potentially reducing severe complications and mortality.
• Employees: Strengthened company pipeline and strategic direction may lead to increased stability and growth opportunities.
• Creditors: The acquisition involves assumed liabilities and future payment obligations, which will be factored into the company's financial health and risk profile.

Next Steps

• Complete database lock for the VLX-1005 Phase 2 PoC study (ALATHEA) in Q1 2026.
• Conduct data analysis and prepare a publication manuscript for VLX-1005 in Q1 2026.
• Design the pivotal protocol for VLX-1005 in 2026.
• Hold an FDA EOP2 Meeting for VLX-1005 in 2026.
• Achieve CMC Readiness for VLX-1005 in 2026.
• Initiate study start-up for the pivotal VLX-1005 study in 2027.
• Initiate the pivotal VLX-1005 study in 2027.
• Begin quarterly payments of Past Patent Costs to Old Dominion University starting March 31, 2026.
• First minimum annual royalty payment to Old Dominion University due May 1, 2029.

Key Dates

Recommendation

The acquisition of VLX-1005 is a highly strategic move for Cadrenal Therapeutics, immediately adding a first-in-class, Phase 2 asset with significant market potential in Heparin-Induced Thrombocytopenia (HIT). The drug's unique mechanism of action, favorable safety profile in Phase 1, and encouraging interim Phase 2 results suggest a strong therapeutic advantage over existing treatments. The FDA's Orphan Drug and Fast Track designations further de-risk the development pathway and indicate regulatory support. While future milestone and royalty payments represent contingent liabilities, they are tied to successful development and commercialization, aligning the company's financial commitments with its progress. This acquisition significantly enhances Cadrenal's pipeline and market positioning in the high-growth anticoagulation sector, making it a compelling investment opportunity for long-term growth.

Keywords

Cadrenal Therapeutics, VLX-1005, Veralox Therapeutics, Acquisition, Heparin-Induced Thrombocytopenia, HIT, 12-LOX Inhibitor, Anticoagulation, Orphan Drug Designation, Fast Track Designation, Biopharmaceutical, Clinical-stage asset, Pharmaceutical pipeline, Thrombosis, Drug development